menu
    • menu
    [{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series B Financing","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Private Placement","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ OrbiMed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Private Placement","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ OrbiMed","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ OrbiMed"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Atlas Venture","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Pharma Plc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bempikibart","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Pharma Plc","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Horizon Pharma Plc"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bempikibart","moa":"IL-7- alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ADX-097","moa":"Complement pathway","graph1":"Dermatology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Inapplicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Bempikibart","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Q32 Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Q32 Bio \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Q32 Bio

    Menu

    Q32 Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q32 Bio Updates Bempikibart Program for Alopecia Areata Development

                            Details : ADX-914 (bempikibart), is a fully human anti-IL-7Rα antibody, which is currently being developed for the treatment of patients with alopecia areata.

                            Product Name : ADX-914

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q32 Bio Completes Enrollment in Phase 2 Trial of Bempikibart for Atopic Dermatitis

                            Details : ADX-914 (bempikibart), is a fully human anti-IL-7Rα antibody, being developed in a Phase 2 trial for the treatment of atopic dermatitis (AD).

                            Product Name : ADX-914

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : OrbiMed

                            Deal Size : $42.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Q32 Bio Closes Merger with Homology Medicines and Raises $42 Million

                            Details : Proceeds will advance the clinical development of Q32 Bio’s assets: ADX-914 (bempikibart) in Phase 2 for atopic dermatitis and ADX-097 in Phase 2 for complement disorders.

                            Product Name : ADX-914

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 25, 2024

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : OrbiMed

                            Deal Size : $42.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : OrbiMed

                            Deal Size : $42.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Q32 Bio and Homology Medicines Announce Merger Agreement

                            Details : The proceeds will be used to advance the clinical development of Q32 Bio’s two wholly owned assets, ADX-914 (bempikibart), in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment o...

                            Product Name : ADX-914

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            November 16, 2023

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : OrbiMed

                            Deal Size : $42.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Horizon Pharma Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerl...

                            Details : ADX-914 (bempikibart) is a fully human anti-IL-7R alpha antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, which is investigated for the treatment of severe alopecia areata.

                            Product Name : ADX-914

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 13, 2023

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Horizon Pharma Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Horizon Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic D...

                            Details : ADX-914 is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP in patients suffering from moderate to severe atopic dermatitis.

                            Product Name : ADX-914

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Horizon Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Horizon Therapeutics

                            Deal Size : $700.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases

                            Details : Under the terms of the agreement, Horizon will fund development through completion of the two Phase 2 trials of ADX-914, with Q32 being operationally responsible for the conduct of all program-related activities.

                            Product Name : ADX-914

                            Product Type : Antibody

                            Upfront Cash : $55.0 million

                            August 15, 2022

                            Lead Product(s) : Bempikibart

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Horizon Therapeutics

                            Deal Size : $700.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-097

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrati...

                            Details : Data for ADX-097, a bi-functional fusion protein comprising a humanized anti-C3d monoclonal antibody showed that C3d-mediated tissue targeting of factor H results in potent, durable and efficacious local complement blockade without systemic complement in...

                            Product Name : ADX-097

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 23, 2022

                            Lead Product(s) : ADX-097

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-097

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders

                            Details : In preclinical studies, ADX-097 demonstrated the potential to potently inhibit disease-causing complement activation in the tissue while avoiding systemic complement inhibition.

                            Product Name : ADX-097

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 26, 2022

                            Lead Product(s) : ADX-097

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed

                            Q32 Bio

                            U.S.A arrow
                            Plastics Recycling EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-097

                            Therapeutic Area : Nephrology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American So...

                            Details : ADX-097 is a first-in-class fusion protein that Q32 Bio is developing to restore innate immune balance via targeted regulation of the complement cascade directly in diseased tissue without long-term systemic blockade.

                            Product Name : ADX-097

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 18, 2021

                            Lead Product(s) : ADX-097

                            Therapeutic Area : Nephrology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth